Caspofungin acetate + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Invasive Candidiasis
Conditions
Invasive Candidiasis
Trial Timeline
Dec 1, 2010 → Apr 1, 2012
NCT ID
NCT01045798About Caspofungin acetate + Placebo
Caspofungin acetate + Placebo is a phase 2 stage product being developed by Merck for Invasive Candidiasis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01045798. Target conditions include Invasive Candidiasis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01045798 | Phase 2 | Terminated |
Competing Products
20 competing products in Invasive Candidiasis